The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback